Systems, methods, and/or apparatuses may be operative to perform a dialysis process that includes a displacer infusion process. In one embodiment, a method for determining a displacer compound may include constructing a plurality of target protein quantitative structure-activity relationship (QSAR) models, one for each of the plurality of binding sites, analyzing a set of candidate compounds using the plurality of QSAR models to determine a set of at least one potential compound with an affinity for binding to each of the plurality of binding sites, and selecting at least one displacer compound from the set of at least one potential compound. Other embodiments are described.

Compounds, systems, kits, methods, and/or apparatuses may be operative to reduce amyloid beta (A) peptide in a patient, including a central nervous system (CNS) of the patient and/or a periphery (non-CNS portion) of the patient. In some embodiments, a displacer fluid comprising a A displacer may be introduced to the patient to bind to a blood protein, such as albumin, that binds A (for instance, A peptide or non-plaque A) in the patient periphery. Binding of the displacer to the blood protein may facilitate more free A peptide (for instance, A monomers) in the periphery for clearance via natural processes, such as through the liver or kidneys, and/or artificial processes, such as dialysis. Increased removal of the free A peptide in the periphery may ultimately lead to less A peptide in the CNS, which may decrease A plaque formation in Alzheimer's Disease (AD) patients. Other embodiments are described.